Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.3389/fgene.2017.00040

http://scihub22266oqcxt.onion/10.3389/fgene.2017.00040
suck pdf from google scholar
C5385377!5385377!28443132
unlimited free pdf from europmc28443132    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi


Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534
pmid28443132      Front+Genet 2017 ; 8 (ä): ä
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Disease Resistance and the Definition of Genetic Enhancement #MMPMID28443132
  • So D; Kleiderman E; Touré SB; Joly Y
  • Front Genet 2017[]; 8 (ä): ä PMID28443132show ga
  • Recent gene editing experiments carried out in human embryos have raised the question of whether interventions like the introduction of a CCR5-?32 deletion, which could provide heritable resistance to HIV infection, ought to be considered enhancements. Many authors have used the term ?enhancement? in different ways, some based on patients? biomedical outcomes and others on their social context. These classifications are often considered overly imprecise. Nevertheless, the concept of ?enhancement? could affect the ways in which these applications are regulated in different jurisdictions, the availability of coverage by insurers or public health care, and the force of public opinion in shaping future policy on gene editing. In order to ethically situate resistance to communicable disease with reference to other techniques, this article provides an overview of its similarities and differences with disease gene therapy in embryos, gene therapy in consenting adults, and vaccination. In discussing key ethical features of CCR5-?32 deletion (including its frequency in various populations, biological mechanism, benefits for individuals, and use in previous clinical trials) we offer some potential guideposts for the continuing discussion on how to classify ?enhancements? in the age of CRISPR gene editing.
  • ä


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box